Single center, open label, phase I study of intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma
Phase of Trial: Phase I
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs HER2 taNK (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms CAR2BRAIN
- 14 May 2019 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
- 14 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
- 13 Feb 2018 According to a NantKwest media release, the first patient has been dosed in this trial.